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Tumor budding (TB) is an important prognostic parameter in colorectal cancer (CRC)
and associated with metastasis. However, the mechanisms of TB have not been fully
elucidated and a major limitation is the absence of in vivo models. Here, we determine
the suitability of human cell line derived xenografts (CDX) as models of TB in CRC.
Pan-cytokeratin (CK)-stained next-generation Tissue Microarrays (ngTMA) of two CDX
models (HT-29, n = 12 and HCT-8, n = 8) and human CRC (n = 27 high-grade and
25 low-grade budding tumors, each) were evaluated for TB. Immunohistochemistry for
E-cadherin, β-catenin, Ki-67, ZEB1, and TWIST1 was performed. HT-29 and HCT-8 were
predominantly high-grade and no/low-grade TB tumors, respectively. TB counts in the
tumor center (intratumoral budding, ITB) were significantly higher in HT-29 CDX tumors
compared to human CRC (p = 0.0099). No difference was found in TB counts at the
invasion front (peritumoral budding, PTB; p= 0.07). ITB and PTBwere strongly correlated
(r = 0.438 and r = 0.62 in CDX and human CRC, respectively). Immunohistochemistry
profiles were comparable in CDX and human CRC tissues. TB in the CDX mouse models
is phenotypically similar to human CRCs and highlights comparable protein profiles. The
HT-29 CDX could be a suitable model for the in vivo assessment of TB.
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INTRODUCTION
Tumor budding (TB) in colorectal cancer reflects the detachment of tumor cells from the main
tumor mass and is defined by the presence of single tumor cells or small tumor cell clusters.
Although typically described at the invasion front (peritumoral budding, PTB), TB can also be
investigated within the tumor center (intratumoral budding, ITB). Studies have shown that both
ITB and PTB can potentially be useful criteria in the clinical management of CRC patients (1–3).
The “International Tumor Budding Consensus Conference” (ITBCC) presented guidelines for the
evaluation of TB, which is useful in two clinical scenarios (4): First, the presence of high-grade PTB
at the invasion front in endoscopically resected pT1 colorectal tumors is positively associated with
lymph node metastasis. These patients are therefore recommended to undergo surgical resection.
Second, high-grade PTB in patients with stage II colorectal cancers have unfavorable prognosis and
are recommended for adjuvant chemotherapy. A third scenario currently under investigation is the
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presence of ITB in preoperative biopsies of patients with neo-
adjuvant treated rectal cancer, which may help predict the
presence of the presence of lymph node and distant metastases
(5, 6).
TBmay also reflect cancer cells in an hybrid state of epithelial-
mesenchymal transition [EMT; (7)]. Immunohistochemical
studies have indeed repeatedly shown both increased nuclear β-
catenin and reduced E-cadherin levels in the TBs compared to
the tumor center. Others report the expression of EMT inducers
such as ZEB1 and TWIST1 in surrounding fibroblasts, hence
promoting the tumor budding phenotype. A major limitation to
the understanding of the underlying mechanisms of TB is the
absence of in vivo models. The aim of this study is to investigate
whether CRC cell line derived xenograft mouse models (CDX)
showTB that is phenotypically similar to human cancers and thus
suitable as model for the study of TB in CRC.
METHODS AND MATERIALS
Tissue
Human
Hematoxylin-eosin (HE) stained slides from 52 consecutive
patients with resected primary CRC treated at the Hôpital
Erasme in Brussels, Belgium (Université Libre de Bruxelles)
between 2015 and 2017 were retrieved from the Department
of Pathology. These slides were then pre-reviewed for TB and
one representative slide per case was selected. Twenty-seven
high-grade budding cases and 25 low-grade budding cases were
identified. The corresponding formalin-fixed, paraffin-embedded
tissue blocks were retrieved from the archives of the Department
of Pathology. The use of this material was approved by the local
ethics committee of the hospital (Ref. No. P2018/126).
Mouse
The study was conducted on 6-year old female immune-deficient
Swiss nu/nu mice (Charles River Laboratories, l’Arbresle Cedex,
France). The mice were injected with cancer cells from 4 different
human CRC cell lines (HCT-8, HT-29, COLO320, RKO). The cell
lines were purchased from the American Type Culture Collection
(ATCC). The animal studies were approved by the Animal Ethics
Committee of Ghent University, Belgium.
The cancer cell implantation was done by a surgical procedure
under general anesthesia (IsoFlo, Abbott, Belgium) and analgesia
(Ketoprofen, 5 mg/kg). After a small midline laparotomy, the
caecum of the mouse was located and gently exteriorized.
The tumor cells were injected into the caecal wall. The
appearance of a small bleb marked the successful implantation.
Finally, the caecum was carefully returned to the abdominal
cavity and the laparotomy was closed. After implantation,
tumor development was assessed weekly by bioluminescence
imaging until 6 weeks after inoculation. The animals were
sacrificed when signs of disease (rectal prolapse, obstruction
of the large bowel and intussusception of the caecum) were
observed. Necropsy was performed and organs were sampled
for histological examination. Formalin-fixed, paraffin-embedded
tissue blocks were generated from each CRC models and H&E
slides examined. However, upon preliminary screening for tumor
budding, only two models were selected for subsequent analysis:
HT-29 and HCT-8, a high-grade and a low-grade budding model,
respectively. Details regarding the models can be found in the
papers of Tommelein and colleagues (8, 9).
Immunohistochemistry Staining of
Whole Slides
Each block was sectioned at 2.5µm and immunohistochemistry
(IHC) for cytokeratin (CK) was performed on an automated
immunostainer (Leica Bond RX, Leica Biosystems). Pan-CK
markers were used to stain epithelial cells. To avoid cross-
reactivity, a mouse antibody was used on human samples
(AE1AE3, Dako M3515, 1:200, DAB as brown) while a rabbit
antibody was used for mouse tissues (Pancytokeratin, Novus
Biological NB600-579, 1:200, DAB as brown). Then all samples
were incubated with HRP (Horseradish Peroxidase)-polymer for
15min and subsequently visualized using 3,3-Diaminobenzidine
(DAB) as brown chromogen (Bond polymer refine detection,
Leica Biosystems, Ref DS9800) for 10 min.
Scanning and Next-Generation Tissue
Microarray (ngTMA®) Construction
All CK-stained slides were scanned using a slide scanner
(Pannoramic P250, 3DHistech, Hungary). Scans were uploaded
onto a case-managing platform (Case Center, 3DHistech,
Hungary). Each scan was then re-reviewed for the presence of TB
and the following annotations of 1.0mm in diameter were made
using a digital TMA annotation tool:
• cases of low-grade budding: 3x tumor center with a
blue annotation,
• cases of high-grade budding: 3x tumor center with a blue
annotation and 3x budding areas at the invasion front with a
red annotation
The tissue blocks were loaded into a semi-automated tissue
microarrayer (TMA Grandmaster, 3DHistech, Hungary).
Annotated digital scans were aligned with an image of the
corresponding tissue block and punched out in the annotated
regions, ensuring the capture of TB. Punched cores were
transferred into a recipient paraffin block. This led to the
construction of three ngTMAs; two containing human tissue,
one with the low-grade budding tumors (75 spots) and one
including the high-grade budding tumors (149 spots). The third
TMA (84 spots) contained all mouse tissue.
Immunohistochemistry Staining of
the TMAs
All ngTMA blocks were sectioned at 2.5µm and underwent
HE staining and single IHC for CK as described above. The
human and mouse ngTMAs were additionally stained for E-
cadherin, β-catenin, Ki-67, ZEB1, TWIST1. Mouse antibodies
were evaluated in parallel with the negative control in mouse
tissue. This Negative control was the same mouse tissue, stained
only with secondary antibody, to identify the cross-reactivity
area and positive cells. Double-staining for Ku-80 and Vimentin
was performed on the mouse ngTMA: In a first step, Ku-80, a
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nuclear marker specific for human cells was visualized using DAB
(brown). In a second step, AP (Alkaline phosphatase)-polymer
for 15min, was used to identify the Vimentin and visualized using
fast red as red chromogen (Red polymer refine Detection, Leica
Biosystems, Ref DS9390).
Finally, the samples were counterstained with hematoxylin
and mounted with Aquatex (Merck). All information on
antibodies and protocols can be found in Supplemental Table 1.
Evaluation
Each TMA core was evaluated for the presence of TB and
manually counted according to the definition of Koelzer et al.
(10). Namely, TBs were defined as single cells or small clusters
of cells in the peritumoral stroma, in which the nucleus
is clearly identifiable. Cytoplasmic pseudofragments, ruptured
glands, mucin pools, and necrosis were excluded. According
to the ITBCC guidelines, the size of tumor buds was limited
to 4 cells (4). In addition to counts of CK-positive cells
in the mouse TMA, expression of Ku-80 was evaluated, to
ensure that structures identified as TBs were indeed of human
origin. For all other markers, expression patterns were described
based on visual assessment. Focus was placed on disrupted
E-cadherin from the membrane, nuclear expression of beta-
catenin, nuclear expression of Ki-67 in TB, as well as nuclear
expression of ZEB1 and TWIST1 in both tumor buds and
surrounding fibroblasts.
A detailed workflow is available in Georges (11).
Statistical Analysis
Descriptive statistics were performed on TB counts in the tumor
center and at the invasion front from all three arrays, including
mean, median, minimum, and maximum scores. The difference
in TB counts in human and mouse high-grade budding cases
was analyzed using a non-parametric Wilcoxon Rank Sum test.
FIGURE 1 | Panel with representative images of the human and mouse CRC stained in CK. Overview of the tumor at 5x magnification, the tumor’s corresponding
center and invasion front at 40x magnification.
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FIGURE 2 | Panel with representative images of the same region at the invasion front of a mouse HT-29 tumor, stained in CK (A) and double-stained in Ku-80 and
Vimentin (B), at 40x magnification. It shows the tumor cells including TBs stained positive for Ku-80, proving their derivation from the human cell line. The tumor
stroma is stained for vimentin in red. The normal intestinal mucosa of the mouse is negative for Ku-80.
TABLE 1 | Descriptive scores of TBs in human cancers and mouse xenograft models, in the tumor center and at the invasion front.
Budding status n◦ of cases n◦ of cores Mean Median Minimum Maximum
Tumor Center (n◦ of buds per core)
Mouse Low (HCT-8) 8 19 2,79 1 0 11
High (HT-29) 12 33 22,64 14 0 88
Human Low 25 75 1,68 0 0 19
High 25 75 11,96 3 0 121
Invasion Front (n◦ of buds per core)
Mouse Low (HCT-8) 8
High (HT-29) 12 29 45,00 47 4 91
Human Low 25
High 25 74 30,31 22 0 156
TB was not evaluated at the invasion front for the low-grade budding tumors.
Analyses were performed using SAS v9.2. P-values < 0.05 were
considered statistically significant.
RESULTS
Overview of Cases
Representative images of human and mouse tumors are found in
Figure 1. Both the human high-grade budding tumors and the
HT-29 CDX mouse models show single cells and small clusters
of cells infiltrating the stroma. The definition of TB was easily
applied to mice. The buds were very similar in size and shape.
However, the human tumors showed a more spacious spread of
TBs within the surrounding stroma. Positive staining for Ku-80
confirmed that CK-positive-appearing TBs in the mouse are in
fact derived from the human cell line. Representative images can
be found in Figure 2.
Difference in TB Counts Between Human
CRC and Mouse CDX Model
TB counts were evaluated in each TMA core. Descriptive
statistics are found in Table 1. In total, 20 mouse tumors were
analyzed, including 8 low-grade (HCT-8) and 12 high-grade
budding tumors (HT-29). The mean number of buds per TMA
core in the tumor center was 2.79 and 22.64, respectively. In
the front, the average number of buds in the high-grade model
was 45.0. The correlation between the count of TBs in the center
(ITB) and the invasion front (PTB) was moderate for the HT-29
model (r = 0.438).
Similarly, in human cases, tissue of 50 patients was analyzed,
including 25 low-grade and 25 high-grade budding cancers. The
average budding counts per TMA core in the center were 1.68 and
11.96, respectively. At the invasion front of high-grade budding
tumors, the average number of TBs per TMA core was 30.3.
Again, ITB and PTB counts were highly correlated (r = 0.62).
Strikingly, the number of tumor buds within the tumor center
of the high-grade budding tumors was significantly different
between mouse and human, the former showing two times more
budding counts than the human tissue (p = 0.0099). At the
invasion front, in cores selected for high numbers of TBs, a non-
significant difference was observed between mouse (45 buds on
average) and human (30.3 buds on average; p= 0.07), despite the
number of TBs still being markedly higher in the mouse.
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TABLE 2 | Description of the expression of proteins, typically associated with EMT
and Tumor Budding (TB), in the budding population in the human and
mouse tumors.
Human TB Mouse TB
β-catenin Predominantly membranous
and cytoplasmic staining in
the TBs
Downregulation of
membranous expression
compared to the tumor
center
Rarely nuclear staining in
TBs, but only when center
also has nuclear staining
Predominantly membranous
and cytoplasmic staining in
the TBs
Downregulation of
membranous expression
compared to the tumor
center
No nuclear staining of
the TBs
Twist1 Nuclear staining of the
mesenchymal cells
Abundant stromal positivity
Zeb1 Nuclear staining of the
mesenchymal cells
Nuclear staining of the
mesenchymal cells
Ki-67 Fewer cells of the TB
population are positive,
compared to the
tumor center
Fewer cells of the TB
population are positive,
compared to the
tumor center
E-cadherin Downregulation of
membranous expression in
the TBs
Downregulation of
membranous expression in
the TBs
Immunohistochemistry Patterns in Human
CRCs and Mouse CDX Models
IHC stainings of the human and mouse tumors show that
proteins, typically associated with EMT and budding are similarly
expressed in both situations. The detailed description can be
found in Table 2 along with representative images in Figure 3.
DISCUSSION
The novel findings of this study show that different orthotopic
mouse xenograft models (HT-29 and HCT-8) can show a
range of TB counts in both the center and the invasion
front similar to what is seen in human tumors. Moreover, the
immunohistochemistry pattern identified in human CRC tissues
is concordant with that in mouse CDX models, suggesting that
the latter may be appropriate for investigation of TB in vivo.
We used CK staining for evaluation of TB for several reasons:
first, previous studies have reported 3-6x more TBs counted
on CK in comparison to HE stains, second, the inter-observer
agreement of budding in CK stains is markedly improved (12),
third TBs can be camouflaged within the dense peritumoral
stroma or inflammation, while on the other hand activated
fibroblasts can be mistakenly identified as TBs (10). In a second
step, we could confirm the presence of both PTB and ITB within
the mouse tumors. Cells identified as TBs based on CK stains
were also positive for Ku-80, confirming that budding cells were
correctly interpreted as buds deriving from the human cell line.
Next, the correlation between ITB and PTB counts was
evaluated. A strong positive correlation was observed in both
human and mouse. It has previously been shown in human
CRC, that budding within the main tumor mass is associated
with budding at the invasion front (5). Our study shows that
FIGURE 3 | Panel with representative examples of TB in human high-grade
budding tumors and HT-29 model, stained using different IHC markers at 40x
magnification.
the same observation can be made in the orthotopic mouse
xenograft model.
A subgroup analysis of high-grade budding tumors produced
two important results. First, a significantly greater number of TBs
was found within the center of mouse tissues, as compared to the
center of human tissues. Although, it may be hypothesized that
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this result was due to the methodology of implanting cells into
the caecum of the mice, the same observation of high numbers of
buds in the low-grade budding mouse tissues should have been
made but was not. This suggests a real biological phenomenon
and not a consequence of the implantation method. Second,
although higher numbers of TBs were found at the invasion front
of the mouse tissues in comparison to the humans, the difference
was not statistically significant.
We found similar immunohistochemistry expression profiles
of the investigated proteins between human and mouse tissues.
Previous laser capture microdissection studies in both CRC and
oral squamous cell carcinomas show that tumor buds over-
express EMT-related genes such as ZEB1, ZEB2, DES, TGFB3,
and VIM in comparison to the main tumor mass (13, 14).
We have also recently found that TB is significantly associated
with the highly unfavorable CMS4 prognostic subgroup of
the Consensus Molecular Subtypes, which is characterized as
a “mesenchymal” subgroup of cancers overexpressing genes
involved in EMT, TGF-beta activation, matrix re-modeling and
WNT signaling (15, 16). We have also previously found that
tumor buds show little Ki-67 staining, indicating their more non-
proliferative nature (17). Results of this study are consistent with
previous reports showing disrupted E-cadherin and infrequent
Ki-67 staining. However, nuclear β-catenin staining was rare in
TB and in our hands, was only found in cases where the main
tumor also showed nuclear staining. Expression of ZEB1 and
TWIST1 was found in the stromal cells in both human and
mouse samples. This has previously been described in colorectal
cancers and pancreatic ductal adenocarcinomas (18, 19). In
fact, previous findings have shown strong correlations between
TWIST1 positivity in fibroblasts and high-grade tumor budding
areas. Interestingly, TWIST1 expression may be epigenetically
regulated as shown by hypermethylation of the promoter region
in stromal areas containing low /absent numbers of tumor buds.
Interesting is also that the two models showed such a range
of budding counts, with the HT-29 being considered as a “high-
grade” model and HCT-8 as a “non-/low-budding” one. Mice of
both models lack an adaptive immune system. Here, we see both
the presence and absence of TB in a tumor microenvironment
without lymphocytes, suggesting that the underlying process of
TB may be independent of the immune response. Nonetheless,
reports suggest an inverse correlation between budding and
the presence of peritumoral lymphocytic inflammation at the
invasion front of cancers, particularly those with Microsatellite
Instability (MSI) suggesting the immune system’s reaction, and
targeted destruction of TB (20).
We are not the first to look at a model of budding in
an animal. Prall et al. took primary CRC from patients and
transplanted these subcutaneously into mice. These patient-
derived xenografts (PDX) also showed TB and podia formation
similar to what was found in the primary diagnostic material
(21). Although such an approach will allow the study of budding
a personalized way in vivo, there may be several associated
disadvantages, such as low success rates of the xenografting
process and limited reproducibility. The approach presented in
our current study used CDX models from two well-established
cell lines and implantation of cells directly into the cecum. This
has the additional advantage of studying TB in the target organ,
namely the colon.
The use of digital pathology in this study had two
major advantages. First, by evaluating digital scans of
CK stained tumors, we could precisely annotate high-
grade budding areas in multiple regions. These precise
regions were captured and transferred into a ngTMA,
which allows us to perform stainings to evaluate the same
buds on serial cuts using different biomarkers. Serial
alignment of images for cross-checking of tumor buds
was possible using a scan viewer software. A limitation of
this study is the annotation of areas of the tumor center
which were not specifically selected to represent regions
of budding. Nonetheless, since multiple regions of each
tumor were annotated, we believe that the degree of ITB is
accurately represented.
To summarize, this study shows that orthotopic mouse
xenograft models from the human HT29 cell line and HCT-
8 cell line are phenotypically similar to TB in human CRC,
suggesting that these models can be further used to help elucidate
the possible mechanisms behind TB in CRC.
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